C4 Therapeutics, Inc. (CCCC) C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
C4 Therapeutics, Inc. NASDAQ:CCCC Healthcare · Biotechnology
Mkt Cap $414.59M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
C4 Therapeutics unveiled a DNA-encoded library (DEL) capability integrated into its TORPEDO platform to accelerate target-first discovery of molecular glue degraders.
The company says the technology has delivered attractive hits against high-value targets within four months, including validated hits for VAV1, which it will not advance without a partner.
C4T remains focused on advancing cemsidomide clinically and on discovery targets driving inflammation and neurodegenerative disease; the announcement is a platform milestone rather than a clinical or financial catalyst.
• 3d ago AI analysis › Press Release
Insmed Appoints Two New Directors to Its Board
Insmed (INSM) appointed Paul Hudson, former CEO of Sanofi, and Utpal Koppikar, CFO of Verily Health, as independent directors.
The FILER, C4 Therapeutics (CCCC), appears only because Koppikar currently sits on its board; CCCC itself has no change in leadership, strategy, or operations from this release.
Any read-through for CCCC is limited to reputational signal — a sitting C4 director joining a larger biopharma's board — and carries no material financial impact.
• 12d ago AI analysis › Press Release ⚠ 2
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
C4 Therapeutics presented new biomarker data at the IMS Annual Meeting showing cemsidomide drives robust T-cell activation and NK-cell reprogramming in 62 heavily pre-treated relapsed/refractory multiple myeloma patients.
The safety data review committee declared the first 75 µg cemsidomide dose level safe in the Phase 1b trial combining cemsidomide with elranatamab (ELREXFIO), advancing the study into dose escalation at 100 µg and a 75 µg expansion cohort.
Preliminary biomarker data from the first two Phase 1b patients showed CD8+ T-cell expansion and prevention of T-cell exhaustion, supporting cemsidomide as a potential backbone combination partner; full Phase 1b cohort data are expected in mid-2027.
• 1mo ago AI analysis › Press Release ⚠ 1
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
C4 Therapeutics announced that new biomarker data on cemsidomide in combination with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial will be presented in a poster at the 23rd International Myeloma Society Annual Meeting in Glasgow, September 23-26, 2026.
The data characterize the compound's immune effects on T cells and natural killer cells across once-daily dose levels, which the company frames as supporting cemsidomide's potential as a combination partner for immune-based therapies.
No new clinical efficacy or safety results were disclosed in the announcement; the poster will be presented September 25, 2026 by Riadh Lobbardi, Senior Director of Translational Medicine.
• 1mo ago AI analysis › Press Release
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics reported Q2 2026 revenue of $6.6 million, driven by the new Roche DAC collaboration, while narrowing its net loss to $23.6 million or $0.18 per share.
The company ended the quarter with $300.4 million in cash, bolstered by a $20 million Roche upfront payment and $33.5 million in ATM proceeds, which extends its operational runway into the end of 2028.
Operationally, the Phase 2 MOMENTUM trial for cemsidomide remains on track to complete enrollment in Q1 2027, with recent data showing overall response rates of up to 53% at the highest dose levels.
• 2mo ago AI analysis › Press Release
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced that its Board's independent directors approved an inducement grant of non-qualified stock options to purchase 162,880 shares of common stock to a new employee.
The grant was made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for the individual to enter employment, with an exercise price equal to the closing price on the grant date.
The options will vest over a four-year period, with 25% vesting on the first anniversary of the start date and the remainder vesting in equal monthly installments.
• 2mo ago AI analysis › Press Release
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
C4 Therapeutics presented Phase 1 data for cemsidomide at the EHA 2026 Congress, showing a 53% overall response rate at the recommended Phase 2 dose in heavily pretreated multiple myeloma patients.
The study included 73 patients with a median of seven prior lines of therapy, many of whom had received prior BCMA or CAR-T treatments. Responses deepened over time, with some patients achieving stringent complete responses and MRD negativity.
The drug was generally well tolerated with manageable neutropenia and minimal dose reductions. These results support the ongoing Phase 2 MOMENTUM trial and potential combination strategies with elranatamab.
• 4mo ago AI analysis › Press Release
C4 Therapeutics to Participate in Upcoming Conferences
globenewswire.com • 5mo ago Press Release
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced the grant of 85,480 non-qualified stock options to a new employee as a material inducement to employment.
The grant was approved by the independent directors and complies with Nasdaq Listing Rule 5635(c)(4), with an exercise price equal to the closing price on the grant date.
The options vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments.
• 5mo ago AI analysis › Press Release ● Major
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com • 5mo ago Press Release
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
globenewswire.com • 6mo ago 
